 -- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924s activation of p21-induced cell cycle arrest in murine bone marrow cells and epithelial mucosa cells in the gastrointestinal GI tract -- 